ClinicalTrials.gg
CompletedNCT02149420CVAY736X2201Updated Oct 4, 2021Results posted

PD of VAY736 in Patients With Primary Sjögren's Syndrome

A Phase 2 interventional study of VAY736 and Placebo in Primary Sjögren's Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study was designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients

Read the detailed description

Patients were enrolled in 2 sequential cohorts:

Cohort 1: 6 patients received 3 mg/kg or Placebo (2:1 ratio) Cohort 2: 21 patients received 10 mg/kg, 3 mg/kg or Placebo (6:1:3 ratio)

At week 24 the blind was broken to assess continuation in the trial:

  • If a patient received VAY736 and their B cell recovery was demonstrated at Week 24, then patients completed the trial.
  • If a patient received VAY736 and their B cell recovery was NOT demonstrated at Week 24, then patients were followed up until B cell recovery was demonstrated
  • If a patient received placebo, they were offered the option of receiving open-label VAY736 (10 mg/kg) in a separate treatment arm.
02

Conditions studied

  • Primary Sjögren's Syndrome

Keywords

  • primary Sjögren's syndrome, pharmacodynamics
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfilled revised European US consensus criteria for pSS
  • ESSDAI value ≥ 6
  • Elevated serum titers at screening of ANA (≥ 1:160)
  • Seropositive at screening for anti-SSA and/or anti-SSB antibodies
  • Stimulated whole salivary flow rate at screening of > 0 mL/min

Exclusion criteria

EXCLUSION CRITERIA:

  • Prior or previous use of (specific dosages and intervals prior to study start may apply): B-cell depleting therapy (e.g., rituximab), Prednisone, anti-BAFF mAb, CTLA4-Fc Ig (abatacept), anti-TNF-α mAb, cyclophosphamide, azathioprine and medications known to cause dry mouth.

Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to randomization is allowed

  • Active or recent history of infection
  • Vaccination within 2 month prior to study
  • History of primary or secondary immunodeficiency
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    VAY736 3 mg/kg

    single dose iv of VAY736 at a dose of 3mg/kg

    Drug: VAY736

  • Experimental
    VAY736 10 mg/kg

    single dose iv of VAY736 at a dose of 10mg/kg

    Drug: VAY736

  • Placebo comparator
    Placebo

    single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)

    The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.

    Time frame: Baseline, week 12

  2. Overall Incidence of Adverse Events

    Number of subjects with Adverse Events during the double blind treatment period.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)

    The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.

    Time frame: Baseline, week 12

  2. Change in Short Form (36) Health Survey (SF-36)

    The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.

    Time frame: Baseline, week 12

  3. Change in Multidimensional Fatigue Inventory (MFI)

    The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.

    Time frame: Baseline, week 12

  4. Change in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)

    The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

    Time frame: Baseline, week 12

  5. Change in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)

    The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

    Time frame: Baseline, week 12

  6. VAY736 Serum Concentration - AUCinf

    The area under the serum concentration-time curve from time zero to infinity \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

  7. VAY736 Serum Concentration - AUClast

    The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

  8. VAY736 Serum Concentration - CL

    The systemic (or total body) clearance from serum following intravenous administration \[volume / time\]. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

  9. VAY736 Serum Concentration - Cmax

    The observed maximum serum concentration following drug administration \[mass / volume\]. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

  10. VAY736 Serum Concentration - T1/2

    Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

  11. VAY736 Serum Concentration - Tmax

    The time to reach the maximum concentration after drug administration \[time\]. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

  12. VAY736 Serum Concentration - Vz

    The volume of distribution during the terminal elimination phase following intravenous administration \[volume\]. The concentration of VAY736 was measured in the serum.

    Time frame: 0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.

07

Results

Posted Feb 12, 2019

Participant flow

A total of 27 patients were enrolled and randomized into the study at one site in Germany.

Core Study
Participant flow — Core Study
MilestonePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
Started9612
Safety analysis set9612
Pk analysis set5612
Pd (pharmacodynamics) analysis set9612
Completed9510
Not completed012
Withdrew: Administrative problems012
Open Label VAY736 10 mg/kg Extension
Participant flow — Open Label VAY736 10 mg/kg Extension
MilestonePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
Started500
Completed400
Not completed100
Withdrew: Administrative problems100

Outcome measures

PrimaryChange in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)

The effect of VAY736 on clinical disease activity was measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The instrument contains 12 organ-specific domains contributing to disease activity. For each domain, features of disease activity are scored in 3 or 4 levels according to their severity. These scores are then summed across the 12 domains in a weighted manner to provide the total score (range 0-123). A reduction from baseline indicates improvement in patients.

Time frame:
Baseline, week 12
Reported as:
Mean · units on a scale
Change in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)
units on a scalePlaceboVAY736 3 mg/kgVAY736 10 mg/kgVAY736 Combined
Baseline11.1 ± 4.0814.5 ± 9.4411.5 ± 4.3812.5 ± 6.38
Week 1210.2 ± 5.2910.7 ± 7.6910.0 ± 5.3610.2 ± 6.01
Change from Baseline to Week 12-0.9 ± 2.98-3.8 ± 8.66-1.5 ± 3.00-2.3 ± 5.40
Statistical analysis
  • Placebo vs VAY736 Combined · repeated measures Bayesian analysis · p = 0.678 · Mean difference (final values): -0.93 · 95% CI -5.007 to 3.180with baseline as a covariate
SecondaryChange in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)

The ESSPRI is a patient self-reported outcome measure to assess dryness, limb pain, fatigue and mental fatigue, where each of the domains normally reported as 0 (not at all) to 10 (extremely severe). The final ESSPRI score is the average of three: dryness, pain and fatigue. A reduction from baseline indicates the improvement of symptoms. During the study all individual scores were reported as 1 to 10 instead. A linear transformation was reported to map the scores to the range of 0-10.

Time frame:
Baseline, week 12
Reported as:
Mean · units on a scale
Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)
units on a scalePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
Baseline5.967 ± 2.21796.049 ± 1.27596.235 ± 1.5379
Week 125.926 ± 1.58226.173 ± 1.47534.568 ± 2.5966
Change from Baseline to Week 12-0.041 ± 1.78050.123 ± 1.0120-1.667 ± 1.8918
SecondaryChange in Short Form (36) Health Survey (SF-36)

The SF-36 is a 36-item, patient self-reported outcome measure (questionnaires) of patient health. The outcome of the questionnaires in eight scales results in two summary scores, physical component and mental component, both ranging from 0 - 100. An increase from baseline in either component summary score indicates reduced disease burden.

Time frame:
Baseline, week 12
Reported as:
Mean · units on a scale
Change in Short Form (36) Health Survey (SF-36)
units on a scalePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
Physical component score: Baseline46.886 ± 6.390539.445 ± 4.285746.015 ± 9.3533
Physical component score: Week 1244.788 ± 8.351345.493 ± 7.306047.671 ± 9.2804
Physical component score: Change from Baseline-2.098 ± 7.90846.048 ± 4.71891.656 ± 5.4113
Mental component score: Baseline36.913 ± 15.277637.517 ± 6.899443.628 ± 11.3667
Mental component score: Week 1241.012 ± 13.299140.170 ± 11.981546.700 ± 11.3182
Mental component score: Change from Baseline4.099 ± 5.33612.653 ± 17.12613.073 ± 11.5823
SecondaryChange in Multidimensional Fatigue Inventory (MFI)

The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue covering the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. Each dimension has a posible range from 4-20. A reduction from baseline in MFI indicates improvement.

Time frame:
Baseline, week 12
Reported as:
Mean · units on a scale
Change in Multidimensional Fatigue Inventory (MFI)
units on a scalePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
General Fatigue: Baseline14.0 ± 4.7217.0 ± 2.3715.9 ± 3.34
General Fatigue: Week 1212.8 ± 4.8414.2 ± 6.4012.4 ± 3.99
General Fatigue: Change from Baseline-1.2 ± 1.64-2.8 ± 5.04-3.5 ± 4.12
Physical Fatigue: Baseline12.9 ± 4.1415.7 ± 2.3414.2 ± 3.41
Physical Fatigue: Week 1212.2 ± 3.9911.2 ± 5.1510.4 ± 4.66
Physical Fatigue: Change from Baseline-0.7 ± 1.32-4.5 ± 6.57-3.8 ± 4.77
Mental Fatigue: Baseline11.9 ± 4.7814.3 ± 3.7813.0 ± 3.28
Mental Fatigue: Week 1211.7 ± 4.1211.3 ± 4.189.8 ± 5.17
Mental Fatigue: Change from Baseline-0.2 ± 2.95-3.0 ± 6.07-3.2 ± 5.84
Reduced motivation: Baseline12.4 ± 4.9312.3 ± 3.9310.9 ± 2.68
Reduced motivation: Week 1212.0 ± 5.3210.0 ± 4.529.8 ± 4.97
Reduced motivation: Change from Baseline-0.4 ± 2.40-2.3 ± 4.50-1.1 ± 4.56
Reduced activity: Baseline11.8 ± 2.8610.8 ± 1.7212.2 ± 2.69
Reduced activity: Week 1210.4 ± 3.818.7 ± 3.619.3 ± 5.08
Reduced activity: Change from Baseline-1.3 ± 1.80-2.2 ± 4.83-2.9 ± 4.25
SecondaryChange in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)

The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

Time frame:
Baseline, week 12
Reported as:
Mean · units on a scale
Change in the Physician's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)
units on a scalePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
Baseline57.3 ± 17.7366.2 ± 17.5365.0 ± 11.74
Week 1259.8 ± 23.3543.0 ± 23.8248.5 ± 17.33
Change from Baseline to Week 122.4 ± 12.21-23.2 ± 31.10-16.5 ± 18.96
SecondaryChange in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)

The visual analogue scale used is a 100 mm VAS ranging from "no disease" (0 mm) to "maximal disease activity" (100 mm).

Time frame:
Baseline, week 12
Reported as:
Mean · units on a scale
Change in the Patient's Global Assessment of Overall Disease Activity by Means of Visual Analog Scale (VAS)
units on a scalePlaceboVAY736 3 mg/kgVAY736 10 mg/kg
Baseline56.2 ± 24.8667.2 ± 13.6959.8 ± 24.30
Week 1255.2 ± 21.5744.2 ± 22.7540.8 ± 20.49
Change from Baseline to Week 12-1.0 ± 17.71-23.0 ± 25.73-19.0 ± 21.08
SecondaryVAY736 Serum Concentration - AUCinf

The area under the serum concentration-time curve from time zero to infinity \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · day*ug/mL
VAY736 Serum Concentration - AUCinf
day*ug/mLVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - AUCinf389 (186 to 457)1140 (515 to 1610)971 (849 to 1340)
SecondaryVAY736 Serum Concentration - AUClast

The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration \[mass × time / volume\]. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · day*ug/mL
VAY736 Serum Concentration - AUClast
day*ug/mLVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - AUClast385 (184 to 457)1140 (514 to 1610)971 (848 to 1340)
SecondaryVAY736 Serum Concentration - CL

The systemic (or total body) clearance from serum following intravenous administration \[volume / time\]. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · L/day
VAY736 Serum Concentration - CL
L/dayVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - CL0.594 (0.427 to 0.844)0.584 (0.550 to 1.30)0.686 (0.427 to 0.750)
SecondaryVAY736 Serum Concentration - Cmax

The observed maximum serum concentration following drug administration \[mass / volume\]. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · ug/mL
VAY736 Serum Concentration - Cmax
ug/mLVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - Cmax65.0 (45.4 to 76.5)213 (150 to 283)205 (174 to 217)
SecondaryVAY736 Serum Concentration - T1/2

Apparent terminal half-life, determined as the ln2/lambda_z or 0.693/lambda_z. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · days
VAY736 Serum Concentration - T1/2
daysVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - T1/28.43 (6.99 to 13.8)9.51 (5.38 to 15.2)11.0 (4.94 to 17.4)
SecondaryVAY736 Serum Concentration - Tmax

The time to reach the maximum concentration after drug administration \[time\]. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · hours
VAY736 Serum Concentration - Tmax
hoursVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - Tmax2.03 (2.00 to 2.20)2.03 (2.00 to 2.30)2.10 (2.02 to 2.17)
SecondaryVAY736 Serum Concentration - Vz

The volume of distribution during the terminal elimination phase following intravenous administration \[volume\]. The concentration of VAY736 was measured in the serum.

Time frame:
0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.
Reported as:
Median · L
VAY736 Serum Concentration - Vz
LVAY736 3 mg/kgVAY736 10 mg/kgOpen Label VAY736
VAY736 Serum Concentration - Vz7.83 (6.55 to 10.7)8.68 (7.15 to 12.4)10.3 (4.93 to 18.6)
PrimaryOverall Incidence of Adverse Events

Number of subjects with Adverse Events during the double blind treatment period.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Overall Incidence of Adverse Events
ParticipantsPlaceboVAY736 3 mg/kgVAY736 10 mg/kgVAY736 Combined
Subjects with AEs861117
Subjects with AEs within 24hr of infusion261117
Subjects with AEs post 24hr of infusion86814
Subjects with Study drug-related AEs561117
Subjects with Infusion related AEs16915

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date subject has provided informed consent until end of study (Week 28 or when B cell recovery was demonstrated, up to 3 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/9 (0%)1/9 (11.1%)9/9 (100%)
VAY736 3mg/kg0/6 (0%)2/6 (33.3%)6/6 (100%)
VAY736 10mg/kg0/12 (0%)0/12 (0%)11/12 (91.7%)
Open Label VAY736 10mg/kg0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboVAY736 3mg/kgVAY736 10mg/kgOpen Label VAY736 10mg/kg
Inguinal herniaGastrointestinal disorders0/90/60/121/5
Jaw fractureInjury, poisoning and procedural complications0/91/60/120/5
Ovarian cyst torsionReproductive system and breast disorders0/91/60/120/5
ColitisGastrointestinal disorders1/90/60/120/5
AppendicitisInfections and infestations1/90/60/120/5
Most frequent other events
Showing 10 of 42
Most frequent other events
EventPlaceboVAY736 3mg/kgVAY736 10mg/kgOpen Label VAY736 10mg/kg
NasopharyngitisInfections and infestations2/95/64/125/5
Infusion related reactionInjury, poisoning and procedural complications1/96/69/123/5
ArthralgiaMusculoskeletal and connective tissue disorders0/92/60/120/5
HeadacheNervous system disorders3/92/62/121/5
Non-cardiac chest painGeneral disorders2/90/60/120/5
PalpitationsCardiac disorders0/90/60/121/5
Vitreous detachmentEye disorders1/90/60/121/5
ToothacheGastrointestinal disorders0/90/60/121/5
BronchitisInfections and infestations0/90/60/121/5
ConjunctivitisInfections and infestations0/90/61/121/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboVAY736 3 mg/kgVAY736 10 mg/kgTotal
Mean46.7 ± 11.2946.8 ± 8.7555.3 ± 13.3550.5 ± 12.16
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVAY736 3 mg/kgVAY736 10 mg/kgTotal
Female751123
Male2114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboVAY736 3 mg/kgVAY736 10 mg/kgTotal
Caucasian961227
08

Study locations

1 site
  • Novartis Investigative Site
    Berlin, 10117, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in Feb 2018, 44 months.

Results were first posted in Feb 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2013
First posted
May 29, 2014
StartActual
May 23, 2014
Primary completionActual
Feb 7, 2018
CompletionActual
Feb 7, 2018
Results first posted
Feb 12, 2019
Last update
Oct 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02149420
Responsible party
Sponsor
First posted
May 29, 2014
Start date
May 23, 2014
Primary completion
Feb 7, 2018
Completion
Feb 7, 2018
Results posted
Feb 12, 2019
Last update
Oct 4, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion